Congressional efforts to end surprise medical billing have a real possibility of succeeding, but recent discussions around transparency have a lot more challenges, said Lauren Vela, senior director of the Pacific Business Group on Health (PBGH).
Congressional efforts to end surprise medical billing have a real possibility of succeeding, but recent discussions around transparency have a lot more challenges, said Lauren Vela, senior director of the Pacific Business Group on Health (PBGH).
Do you think the bill from Senators Lamar Alexander, R-Tennessee, and Patty Murray, D-Washington, can end surprise medical billing?
I do. I mean I do! I think we’re already seeing it. We’ve already seen changes. Elizabeth Mitchell, the chief executive officer of PBGH, testified, as well as others, and we already see changes as a result of that. I think that the American public has said, “Enough is enough. This is not ok.” Our Congress men and women are saying, “Enough is enough. We’re going to make changes.” And this is something they can really understand and sink their teeth into and fix. And I actually anticipate that there will be other good things that come out of the lower healthcare cost bill, but I think surprise billing will be one of those things.
Do you think greater price transparency will result in lower healthcare costs? Will patients actively seek out that information?
We think transparency in healthcare is very, very important. I don’t think it’s the holy grail. I think it’s very, very complicated, and I think often the transparency that’s being spoken of today is not meaningful transparency because it might not actually be transparency about prices that consumers actually pay. So, there’s a lot of caveats in all of that. But moving towards transparency is a good thing.
I also think that where we have had transparency, it hasn’t necessarily been used; so, consumerism hasn’t really worked when we’re depending on the consumer to do a lot of work. Especially if they’re doing work and getting inaccurate information. So, I think there’s a lot of potential and possibility in the space of transparency, it in and of itself is not the only solution but it’s a step in the right direction.
I think part of the problem with our system is that it’s so complicated and untransparent that it has allowed intermediaries and other stakeholders to continue and perpetuate a system where incentives are not aligned. So, having transparency on that will help break down some of those historical paradigms.
What needs to be done to make healthcare more transparent and shoppable?
It needs to be user friendly. Information needs to be user friendly… and you know we have steps to get there. So, the transparency that’s being spoken of today in the executive order and other places is not necessarily the end-all, but it’s a step in the right direction. Because what it really means to be is “very easily accessible at the time when a patient needs it, showing an episode of care, and showing what the patient’s portion of the payment will be.” So, adjusted so it’s showing contractual rates. I mean all of that is going to be really critical to have it be really meaningful to patients, and any transparency that we can do to get there is a good thing.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More